Clinical Characteristics of Patients with Hepatocellular Carcinoma in a Middle Eastern Population
暂无分享,去创建一个
F. Sanai | A. Abdo | Majid Abdulrahman Almadi | A. Albenmousa | W. Al-Hamoudi | K. Alswat | M. Altuwaijri
[1] Z. Abbas,et al. Hepatocellular Carcinoma in Pakistan: Where do We Stand? , 2012, Hepatitis monthly.
[2] F. Sanai,et al. Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines , 2012, Annals of Saudi medicine.
[3] Chien-Jen Chen,et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[5] S. Rha,et al. Gene-expression profiles related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Z. Memish,et al. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[7] M. Zoli,et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? , 2009, European journal of gastroenterology & hepatology.
[8] P. van Damme,et al. The global impact of vaccination against hepatitis B: a historical overview. , 2008, Vaccine.
[9] A. Abdo,et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. , 2008, The Journal of infection.
[10] R. Branch,et al. Gender-based outcomes differences in unresectable hepatocellular carcinoma , 2008, Hepatology international.
[11] Michael Karin,et al. References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .
[12] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[13] K. Mullen. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy , 2007, Alimentary pharmacology & therapeutics.
[14] J. Bruix,et al. Management of hepatocellular carcinoma , 2005, Hepatology.
[15] M. Mohamed,et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. , 2005, World journal of gastroenterology.
[16] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[17] Josepa Ribes,et al. Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.
[18] E. A. Ayoola,et al. Hepatocellular carcinoma in Saudi Arabia: Role of hepatitis B and C infection , 2004, Journal of gastroenterology and hepatology.
[19] P. Tangkijvanich,et al. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. , 2004, World journal of gastroenterology.
[20] M. Colombo,et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. , 2004, Gastroenterology.
[21] Zhao-You Tang,et al. Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.
[22] F. Al-Faleh. Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades. , 2003, Annals of Saudi medicine.
[23] M. Abecassis,et al. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. , 2003, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[24] A. Mitwalli,et al. Hepatitis C virus seroprevalence rate among Saudis. , 2003, Saudi medical journal.
[25] R. Moreau,et al. The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club , 2003, Hepatology.
[26] J. Hoofnagle,et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin , 2003, Hepatology.
[27] J. Dickinson,et al. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. , 2003, The Cochrane database of systematic reviews.
[28] F. Al-Faleh,et al. Efficacy of hepatitis B vaccine in a cohortcommunity-based study in Riyadh and Hail regions of Saudi Arabia. , 2002, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[29] Manal M. Hassan,et al. The Role of Hepatitis C in Hepatocellular Carcinoma: A Case Control Study Among Egyptian Patients , 2001, Journal of clinical gastroenterology.
[30] B. McMahon,et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study , 2000, Hepatology.
[31] J. Bruix,et al. Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma , 2000, Hepatology.
[32] Bernardino,et al. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma , 2000, Hepatology.
[33] S. Chevret,et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. , 1999, Journal of hepatology.
[34] A. Stapleton. Prevention of recurrent urinary-tract infections in women , 1999, The Lancet.
[35] V. Sivasubramaniam,et al. Hepatic tumors in a Saudi patients population. , 1996, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[36] H. Tsukuma,et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.
[37] E. A. Ayoola,et al. Integration of hepatitis B vaccine into the expanded program on immunization: The Saudi Arabian experience. , 1993, Annals of Saudi medicine.
[38] R. Good. Mixed chimerism and immunologic tolerance. , 1993, The New England journal of medicine.
[39] C. J. Chen,et al. Elevated serum testosterone levels and risk of hepatocellular carcinoma. , 1993, Cancer research.
[40] S. Shariq,et al. The association between hepatitis C virus antibody and hepatocellular carcinoma in relation to hepatitis B viral infection (RAFH experinece). , 1992, Annals of Saudi medicine.
[41] E. A. Ayoola,et al. Seroepidemiology of hepatitis B virus infection in Saudi Arabian children: a baseline survey for mass vaccination against hepatitis B. , 1992, The Journal of infection.
[42] Y. Fakunle,et al. Prevalence of antibodies to hepatitis C virus in Saudi patients with chronic liver disease. , 1991, Annals of Saudi medicine.
[43] E. A. Ayoola,et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: A community‐based study , 1991, Hepatology.
[44] J. Bruix,et al. PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSIS , 1989, The Lancet.
[45] S. Ashraf,et al. Hepatitis B virus among saudi children in Gizan, Saudi Arabia , 1986, Infection.
[46] S. Arya,et al. Hepatitis B virus in Gizan, Saudi Arabia , 1985, Journal of medical virology.
[47] M. Ali,et al. Hepatic tumors in Saudi Arabia. A practical approach to diagnosis , 1985, Cancer.
[48] Lu-Yu Hwang,et al. HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.
[49] M. Prates,et al. A cancer survey in Lourenço Marques, Portuguese East Africa. , 1965, Journal of the National Cancer Institute.
[50] N. Chavez-Tapia,et al. Clinical practice guidelines: Management of Hepatocellular Carcinoma , 2014 .
[51] V. Mazzaferro,et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .
[52] E. Soto-Pérez-de-Celis,et al. Epiploic appendagitis: an uncommon nonsurgical cause of acute abdomen , 2012, Annals of Saudi medicine.
[53] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.
[54] F. Sanai,et al. Saudi gastroenterology association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. , 2007, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[55] Stefan Schreiber,et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. , 2007, Gastroenterology.
[56] Bellia Mario,et al. Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) , 2000 .
[57] G. Kovacs. Neuropathology of Neurodegenerative Diseases: Practical approach to diagnosis , 2000 .
[58] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.
[59] N. Chalasani,et al. Predictors of large esophageal varices in patients with cirrhosis , 1999, American Journal of Gastroenterology.
[60] F. Serebour,et al. The aetiology of acute viral hepatitis in the western region of Saudi Arabia. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[61] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.